JAK-ing up chronic actinic dermatitis with upadacitinib.

SKIN inflammation; THERAPEUTICS; MIDDLE-aged men; ATOPIC dermatitis; DELAYED hypersensitivity

This article discusses the use of upadacitinib, a Janus kinase inhibitor (JAKi), as a potential treatment for chronic actinic dermatitis (CAD). CAD is a rare immunologically mediated photodermatosis that causes pruritic, eczematous, and lichenified plaques on sun-exposed areas of the skin. Current treatment options for CAD include topical therapy with corticosteroids and calcineurin inhibitors, as well as oral corticosteroids and immunosuppressive drugs. However, some patients do not respond to these treatments, highlighting the need for novel therapeutic approaches. Upadacitinib has shown promise in treating other dermatoses and has been successful in treating a 75-year-old man with refractory CAD. Further investigation is needed to determine the efficacy of JAKi as a treatment option for CAD. [Extracted from the article]